MAXIPHARMA A/S: Financial statements 2023
CVR: 87375617
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
MAXIPHARMA A/S (CVR 87375617) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,824,624 and a net result of DKK 226,485 compared with DKK 264,940 the year before. That is a decrease of 9.8% compared with the year before. Equity in the 2023 report amounted to DKK 3,766,378. The solvency ratio was 72.3%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 1,824,624
- Profit/Loss
- DKK 226,485
- Equity
- DKK 3,766,378
- Total Assets
- DKK 5,206,259
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 1.8 mio. | 226 t. | 3.8 mio. | 2 |
| 2022 | - | 2 mio. | 265 t. | 3.7 mio. | 2 |
| 2021 | - | 1.7 mio. | 988 t. | 3.7 mio. | 2 |
| 2020 | - | 1.5 mio. | 746 t. | 3.4 mio. | 2 |
| 2019 | - | 1.4 mio. | 774 t. | 2.8 mio. | 2 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
MAXIPHARMA A/S has published its annual report for 2022. Gross profit came to DKK 2,022,230, and the net result was DKK 264,940.
About MAXIPHARMA A/S
MAXIPHARMA A/S is a Danish company of the type Aktieselskab based in Højbjerg, founded in 1979. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jesper Bjerre Jensen. The board consists of Benedikte Mailand Jensen (chair), Henrik Bencke and Jesper Bjerre Jensen. The company is owned by AKTIESELSKABET SGJ. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 1,791,625 and a net result of DKK 434,996 compared with DKK 411,322 the year before. Equity in the 2025 report amounted to DKK 4,204,696.